9:42 AM
 | 
Mar 16, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MyoKardia's mavacamten meets in low-dose cohort of Phase II for cardiomyopathy

MyoKardia Inc. (NASDAQ:MYOK) reported data from the 10 patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM) in the second cohort of the open-label, U.S. Phase II PIONEER-HCM trial showing that lower doses of oral mavacamten met the primary and several secondary endpoints. The company said the data and data from the first cohort will inform the starting dose and guide dose-adjustment in the Phase III EXPLORER-HCM trial of mavacamten in the indication, which is expected to start next quarter.

Patients in the trial’s second cohort were allowed to use background...

Read the full 421 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >